TIDMSAR
RNS Number : 9211Z
Sareum Holdings PLC
20 December 2017
(AIM: SAR) 20 December 2017
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Issue of Options
The Company announces that it granted on 19 December 2017 the
following share options (the "Options") to Dr Tim Mitchell, Chief
Executive Officer, Dr John Reader, Chief Scientific Officer and Dr
Stephen Parker, Non-Executive Chairman.
Drs Mitchell and Reader will each receive an option over
19,097,687 Shares, exercisable by no later than 19 December 2027 in
the case of 9,548,844 Shares at 0.825 pence, 4,774,442 Shares at
1.2375 pence and 4,774,421 Shares at 1.65 pence per Share,
respectively.
Dr Parker will receive an option over 6,545,455 Shares,
exercisable by no later than 19 December 2027, in the case of
3,272,728 Shares at 0.825 pence, 1,636,364 Shares at 1.2375 pence
and 1,636,363 Shares at 1.65 pence per Share, respectively.
Following the grants of Options referred to above, the interests
of Directors in options over Shares will be as follows:
Director Share scheme Exercise No. of Percentage
price Shares of issued
(pence) under share
option capital
Dr Tim Mitchell EMI 0.25 6,400,000 0.23%
EMI 0.26 6,153,846 0.22%
EMI 1.2 2,566,666 0.09%
EMI 0.6 4,752,000 0.17%
EMI 0.425 7,198,353 0.26%
EMI 0.59 5,340,862 0.19%
EMI 0.8 6,250,000 0.23%
EMI 1.2 3,125,000 0.11%
EMI 1.6 3,125,000 0.11%
Unapproved 0.825 9,548,844 0.35%
Unapproved 1.2375 4,774,422 0.17%
Unapproved 1.65 4,774,421 0.17%
Dr John Reader EMI 0.25 6,400,000 0.23%
EMI 0.26 6,153,846 0.22%
EMI 1.2 2,566,666 0.09%
EMI 0.6 4,752,000 0.17%
EMI 0.425 7,198,353 0.26%
EMI 0.59 5,340,862 0.19%
EMI 0.8 6,250,000 0.23%
EMI 1.2 3,125,000 0.11%
EMI 1.6 3,125,000 0.11%
Unapproved 0.825 9,548,844 0.35%
Unapproved 1.2375 4,774,422 0.17%
Unapproved 1.65 4,774,421 0.17%
Dr Stephen
Parker Unapproved 0.8 5,000,000 0.18%
Unapproved 1.2 2,500,000 0.09%
Unapproved 1.6 2,500,000 0.09%
Unapproved 0.825 3,272,728 0.12%
Unapproved 1.2375 1,636,364 0.06%
Unapproved 1.65 1,636,363 0.06%
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and
Co-Broker)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media
enquiries)
Shabnam Bashir/ Mark Swallow/
David Dible 020 7282 9571
Notes for editors:
Sareum is a specialist drug discovery and development company
delivering targeted small molecule therapeutics, focusing on cancer
and autoimmune disease, and generating value through licensing them
to international pharmaceutical and biotechnology companies at the
preclinical or early clinical trials stage.
Its most advanced programme, SRA737, is a novel Checkpoint
kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology
and in clinical trials targeting a range of advanced cancers. The
key role of Chk1 in cancer cell replication and DNA damage repair
suggests that SRA737 may have broad application as a targeted
therapy in combination with other oncology and immune-oncology
drugs in genetically defined patients.
Sareum is also advancing programmes to develop novel tyrosine
kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and
Aurora+FLT3 inhibitors in haematological cancers, which are in the
IND-enabling preclinical and lead optimisation stages.
The Company's drug discovery technology platform (SKIL(R) -
Sareum Kinase Inhibitor Library) is being applied to generate drug
research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
POSBBLFLDLFFFBX
(END) Dow Jones Newswires
December 20, 2017 06:00 ET (11:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024